New drug tested for Tough-to-Treat skin cancer
NCT ID NCT02975700
Summary
This early-stage study tested an investigational drug called PLX3397 in a small group of adults with advanced melanoma that had spread and could not be surgically removed. The cancer also had to have a specific genetic change called a KIT mutation. The main goals were to check the drug's safety, how it moves through the body, and to see if it showed any early signs of helping to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Samsung Medical Center
Seoul, Gangnam-Gu, 06351, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, Seodaemun-gu, 03722, South Korea
-
Sun Yat-sen Hospital
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.